chromium ethylenediaminetetraacetic acid
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02455115)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 51-chromium
Oral
No
Parenteral
No
Topical
No
Also known as
- chromium ethylenediaminetetraacetic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04788680 | N/A | Mar 31, 2021 | University of Vienna |
| NCT04236713 | N/A | Jan 21, 2020 | McMaster University |
| NCT03985371 | Early Phase 1 (Phase 1) | Jul 31, 2019 | Livionex Inc, University of Rochester |
| NCT02455115 | N/A | Jan 1, 2015 | University of Gothenburg |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Livionex Inc | For profit | 1 | 0 | 1 | 2019 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Gothenburg | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1